{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:15:17Z","timestamp":1793812517558,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejca.2022.10.030","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:16:13Z","timestamp":1670670973000},"page":"98-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study"],"prefix":"10.1016","volume":"183","author":[{"given":"J\u00fcrgen","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8801","authenticated-orcid":false,"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-5265","authenticated-orcid":false,"given":"Harry J.M.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gilloteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Le Mouhaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Hampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chassot-Agostinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-5188","authenticated-orcid":false,"given":"Maria","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bintu","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.10.030_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ejca.2022.10.030_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/imj.13132","article-title":"Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre","volume":"46","author":"Denton","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.ejca.2022.10.030_bib3","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1002\/cncr.25681","article-title":"Symptom burden and performance status in a population-based cohort of ambulatory cancer patients","volume":"116","author":"Barbera","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cllc.2016.12.010","article-title":"Evolution of symptom burden of advanced lung cancer over a decade","volume":"18","author":"Sung","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.015","article-title":"Newly diagnosed patients with advanced non-small cell lung cancer: a clinical description of those with moderate to severe depressive symptoms","volume":"145","author":"Andersen","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0885-3924(99)00150-5","article-title":"Symptoms in adults with lung cancer. A systematic research review","volume":"19","author":"Cooley","year":"2000","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.ejca.2022.10.030_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.lungcan.2006.10.001","article-title":"Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress","volume":"55","author":"Graves","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.10.030_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.10.030_bib10","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.10.030_bib11","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/JTO.0000000000000620","article-title":"Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor","volume":"10","author":"Yeung","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.10.030_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.10.030_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","article-title":"Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis","volume":"133","author":"Awad","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib14","series-title":"Capmatinib US prescribing information","year":"2020"},{"key":"10.1016\/j.ejca.2022.10.030_bib15","series-title":"Tepotinib US prescribing information","year":"2021"},{"key":"10.1016\/j.ejca.2022.10.030_bib16","unstructured":"Novartis. Novartis announces MET inhibitor Tabrecta\u2122 approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-met-inhibitor-tabrecta-approved-japan-advanced-non-small-cell-lung-cancer-metex14. Accessed April 1, 2022."},{"key":"10.1016\/j.ejca.2022.10.030_bib17","unstructured":"Novartis. Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-tabrecta-first-published-overall-survival-and-updated-overall-response-data-patients-metex14-metastatic-nsclc. Accessed April 1, 2022."},{"key":"10.1016\/j.ejca.2022.10.030_bib18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"GEOMETRY mono-1 investigators. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.10.030_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review","volume":"23","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.10.030_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer qlq-C30: a quality-of-life instrument for use in international clinical trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2022.10.030_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.10.030_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.030_bib23","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2022.10.030_bib24","first-page":"1023","article-title":"Quality of life of patients with lung cancer","volume":"9","author":"Polanski","year":"2016","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejca.2022.10.030_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.ejca.2022.10.030_bib26","series-title":"Presented at the European Society for Medical Oncology Virtual Congress","article-title":"Health-related quality of life in patients with NSCLC harboring MET exon 14 skipping treated with tepotinib","author":"Garassino","year":"2020"},{"issue":"11","key":"10.1016\/j.ejca.2022.10.030_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.10.030_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:59Z","timestamp":1760733599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"alternative-id":["S0959804922017841"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}